From Wikipedia, the free encyclopedia

CSL Limited
Type	Public ASX: CSL
Founded	1994 (privatised), 1916 (government department)
Headquarters	Melbourne, Australia
Key people	Brian A McNamee (CEO)
Industry	medicine
Products	blood plasma, vaccines, antivenom, other laboratory and medical products
Revenue	$1,500 million AUD (Y.E. 30 June 2004)
Website	www.csl.com.au

CSL Limited is an Australian-based manufacturer of medical products. Its products include various blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing.

Contents 1 History 2 Locations 3 Ownership 4 Products 4.1 CSL Vaccines 4.1.1 Vaccines 4.1.2 Antivenoms 4.2 CSL Pharmaceuticals 4.3 CSL Behring 4.4 CSL Bioplasma 5 See also

Founded in 1916 the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. The operation commenced plasma fractionation in 1952. It was privatised as CSL Ltd in 1994. In 2000 CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring.

The company's headquarters remain in Parkville, Victoria, an inner suburb of Melbourne. CSL Behring is headquartered in King of Prussia, Pennsylvania and has manufacturing operations in the Swiss city of Berne, in Marburg in Germany, and Kankakee, Illinois.

CSL is a public company whose stock is traded on the Australian Stock Exchange under the stock code CSL. The company completed an Initial Public Offering in June 1994 at A$2.30 per share. Today CSL stock is part of the S&P/ASX 50 Index.

CSL Limited's products can be separated by company division. Some of the key products produced by each division, circa 2006, include:

• ADT (acellular diphtheria/tetanus vaccine)
• Comvax (Haemophilus influenzae type B/hepatitis B vaccine)
• Fluvax (influenza vaccine)
• Gardasil (a human papilloma virus vaccine which gained TGA approval in June 2006)
• H-B Vax II (hepatitis B vaccine)
• Liquid PedVaxHIB (Haemophilus influenzae type B vaccine)
• Menjugate (meningococcus group C vaccine)
• Meruvax II (rubella vaccine)
• M-M-R II (MMR vaccine)
• Plague vaccine (Yersinia pestis vaccine)
• Pneumovax 23 (pneumococcus vaccine)
• Q Vax (Coxiella burnetii vaccine)
• Tet-Tox (tetanus vaccine)
• Vaqta (hepatitis A vaccine)
• Varivax (varicella zoster vaccine)

• Black snake
• Box jellyfish
• Brown snake
• Death adder
• Funnel web spider
• Polyvalent snake antivenom
• Red back spider
• Sea snake
• Stonefish
• Taipan
• Tick
• Tiger snake

• Angiomax (bivalirudin) – licenced from The Medicines Company
• Austrapen (ampicillin)
• BenPen (benzylpenicillin)
• Burinex (bumetanide) – licenced from LEO Pharma
• Daivonex (calcipotriol) – licenced from LEO Pharma
• Daivobet (calcipotriol/betamethasone) – licenced from LEO Pharma
• EpiPen (epinephrine autoinjector) – licenced from Dey Laboratories
• Flomaxtra (tamsulosin) – licenced from Astellas Pharma
• Flopen (flucloxacillin)
• Fucidin (fusidic acid) – licenced from LEO Pharma
• Minijet system – preparations include: epinephrine, atropine, calcium chloride, furosemide, glucose, lidocaine, naloxone, sodium bicarbonate
• Modavigil (modafinil) – licenced from Cephalon
• Tramal (tramadol) – licenced from Grünenthal

• Beriate, which is freeze-dried human factor VIII concentrate
• Berinin, freeze-dried human factor IX concentrate
• Helixate FS, freeze-dried recombinant coagulation factor VIII. CSL is working on a new Helixate product called "Helixate NexGen".
• Humate-P, freeze-dried human coagulation factor VIII/von Willebrand factor complex
• Monoclate, a freeze-dried human coagulation factor VIII that has been purified using monoclonal antibodies
• Mononine, a freeze-dried human coagulation factor IX that has been purified using monoclonal antibodies
• Stimate, a synthetic desmopressin acetate nasal spray

• Albumex (serum albumin)
• Biostate (Factor VIII)
• Carimune, which is immunoglobulin for intravenous administration (IGIV)
• CMV Immunoglobulin-VF (cytomegalovirus immunoglobulin)
• Helixate, which is recombinant Antihemophilic Factor, a blood-clotting factor for the treatment of haemophilia
• Hepatitis B immunoglobulin
• human immunoglobulin – Intragam P, Normal, Rh(D) Immunoglobulin-VF, Sandoglobulin,
• MonoFIX-VF (Factor IX)
• Prothrombinex-HT (prothrombin complex)
• Tetanus Immunoglobulin-VF
• Thrombotrol-VF (antithrombin III)
• Vivaglobin, sub-cutaneous human immune globulin indicated for the treatment of primary immunodeficiency. This product gained FDA approval in January 2006.
• Von Willebrand factor
• WinRho SDF (Rh(D) immunoglobulin G)
• Zoster Immunoglobulin-VF (varicella zoster immunoglobulin)

• Australian Red Cross Blood Service